IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 12
- Q1 2026, −10 vs. previous quarter
- 13F value
- $199.0K
- Reported value at the end of Q1 2026
- Superinvestors holding
- 0
- At the end of Q1 2026
Superinvestors holding IOBT, Q1 2026
No superinvestor reported holding IOBT at the end of Q1 2026.
Latest insider trades
Open-market purchases and sales by IO Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2025 (view filing) | May 30 | 3 days | Hunter HeidiDirector | PPurchase | +15.0K | $1.39 | +$20.9K | New position15.0K after | |
| Dec 26, 2024 (view filing) | Dec 23 | 3 days | Ahmad Qasim IftikharChief Medical Officer | PPurchase | +31.4K | $0.85 | +$26.6K | New position31.4K after | |
| Dec 23, 2024 (view filing) | Dec 23 | Same day | Zocca Mai-BrittChief Executive Officer | PPurchase | +12.5K | $0.81 | +$10.1K | +33.4%49.9K after | |
| Dec 23, 2024 (view filing) | Dec 23 | Same day | Sullivan AmyChief Financial Officer | PPurchase | +10.3K | $0.83 | +$8.51K | +13.8%84.6K after | |
| Dec 23, 2024 (view filing) | Dec 23 | Same day | Smith Devin WhittemoreGeneral Counsel | PPurchase | +12.0K | $0.81 | +$9.72K | +243.0%16.9K after | |
| Jul 26, 2024 (view filing) | Jul 25-26 | 1 day | Novo Holdings A/S10% Owner | SSale | −75.0K | $1.32 | −$99.3K | −1.7%4.35M after | 2 lots |
| May 14, 2024 (view filing) | May 10 | 4 days | Novo Holdings A/S10% Owner | SSale | −658.8K | $1.22 | −$803.7K | −12.9%4.43M after | |
| Feb 13, 2024 (view filing) | Feb 9 | 4 days | Novo Holdings A/S10% Owner | SSale | −658.8K | $1.50 | −$988.2K | −11.5%5.09M after | |
| Nov 24, 2023 (view filing) | Nov 21-22 | 3 days | Burkavage BrianChief Accounting Officer | PPurchase | +10.0K | $1.02 | +$10.2K | +666.7%11.5K after | 2 lots |
| Aug 11, 2023 (view filing) | Aug 9 | 2 days | Novo Holdings A/S10% Owner | PPurchase | +2.47M | $2.03 | +$5.01M | +76.2%5.71M after |
Top 10 13F holders, Q1 2026
The largest institutional positions in IO Biotech, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 1,386,565 | $81.4K | 0.01% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 451,852 | $26.5K | 0.00% | 00.0% | Unchanged |
| Gsa Capital Partners LLP | 348,352 | $20.0K | 0.00% | +348,352 | New |
| Marshall Wace, LLP | 301,291 | $18.1K | 0.00% | −128,047−29.8% | Reduced |
| XTX Topco Ltd | 265,792 | $15.6K | 0.00% | +249,928+1,575.4% | Added |
| Morgan Stanley | 206,215 | $12.1K | 0.00% | −332,967−61.8% | Reduced |
| Millennium Management LLC | 194,158 | $11.4K | 0.00% | +55,442+40.0% | Added |
| Citigroup Inc | 72,495 | $4.25K | 0.00% | −38,952−35.0% | Reduced |
| Jane Street Group, LLC | 57,974 | $3.40K | 0.00% | +57,974 | New |
| Beacon Pointe Advisors, LLC | 42,600 | $2.50K | 0.00% | −463,400−91.6% | Reduced |